Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chimerix has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of broad spectrum antiviral drug candidate, CMX001.
Subscribe to our email newsletter
CMX001 is a potential dual-use therapeutic with evidence of antiviral activity against all five families of double-stranded DNA (dsDNA) viruses that cause morbidity and mortality in humans, including smallpox.
Under the terms of the BARDA contract, Chimerix will receive committed funding of $24.8m during the first year with subsequent option periods that, if completed, would bring the total contract value to $81.1m.
The funding from BARDA builds upon the $37m Chimerix previously received from the National Institute of Allergy and Infectious Diseases (NIAID) for development of CMX001 for smallpox.
Chimerix had also received substantial private investment from top-tier venture capital firms for the development of CMX001 as a treatment for other life-threatening infections such as adenovirus and cytomegalovirus.
As part of progressing the clinical and non-clinical development of CMX001 for the smallpox indication, the BARDA contract will also support expanded human safety trials and the recently initiated CMX001-350 multicenter, open-label clinical study of CMX001 for the treatment of twelve life-threatening or serious conditions caused by dsDNA viruses.